Australia invests in local manufacturing of AI tools for respiratory disease - Australian Manufacturing
Summary
Diag-Nose.io secured $3 million in federal funding to advance RhinoMAP, an AI-powered diagnostic platform for respiratory disease. The project will support local manufacturing and clinical validation in Australia. RhinoMAP combines protein biomarkers from nasal fluid with patient-reported data to monitor airway inflammation and treatment response. The company is working with university, medical, and commercial partners to strengthen its precision medicine offering and expand local medical technology capability.
Funding
Amount
$2.0M
Total raised
Date
August 25, 2025
Announcement date
Investors
Monash University
Lead investors
Company
https://www.diag-nose.io
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected